
*
* TRANSACTION REPORT *
*

P. 01

APR-05-06 WED 01:41 PM

DATE START RECEIVER

TX TIME PAGES TYPE

NOTE

M# DP

APR-05 01:37 PM 15712738300

3' 43"

13 SEND

OK

125

* TOTAL : 3M 43S PAGES: 13 *

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association

P.O. Box 142950

Suite A-1

Gainesville, FL 32614-2950

Telephone (352) 375-8100

Facsimile (352) 372-5800

TO: Examiner Chih-Min Kam, Ph.D.

FROM: David R. Saliwanchik

COMPANY: U.S. Patent Office
Art Unit 1653

DATE: April 5, 2006

FAX NO.: (571) 273-8300

NO. OF PAGES
(INCLUDING COVER SHEET): 13

SUBJECT/MESSAGE:

Re: Serial No. 09/641,104; filed August 17, 2000

- 1) Amendment After Allowance Under 37 CFR §1.312 (3 pages); and
- 2) Replacement Table 3 (9 pages).

I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent
and Trademark Office on the date shown below:

April 5, 2006
David Saliwanchik
David R. Saliwanchik, Patent Attorney

AMENDMENT AFTER ALLOWANCE
UNDER 37 CFR §1.312
Examining Group 1653
Patent Application
Docket No. BB-112T
Serial No. 09/641,104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

o.k
to
entw
5/4/06

Examiner	:	Chih-Min Kam, Ph.D.
Art Unit	:	1653
Applicants	:	Walter Birchmeier, Jens-Peter Von Kries
Serial No.	:	109/641,104 <u>09/641,104</u>
Conf. No.	:	5225
Filed	:	August 17, 2000
For	:	Agents for Treating Human Illnesses, Based on Beta Catenin, and the Production and Use Thereof

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AFTER ALLOWANCE UNDER 37 CFR §1.312

Sir:

Please amend the subject application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments follow the amendment sections of this paper.